Latasha Seal, NP
Family · Bean Station, TNNPI 1699931857
Payments from drug & device makers
Across 77 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$325
- Axsome Therapeutics, Inc.$228
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$109
- Sunovion Pharmaceuticals Inc.$93
- GSK$84
- Lilly USA, LLC$75
- plus $390 from 15 others
What the payments were for
- Food & beverage$1,303100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $325 |
| Axsome Therapeutics, Inc. | 14 | $228 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $109 |
| Sunovion Pharmaceuticals Inc. | 5 | $93 |
| GSK | 5 | $84 |
| Lilly USA, LLC | 5 | $75 |
| Novo Nordisk | 4 | $63 |
| Merck | 3 | $48 |
| Eisai Inc. | 2 | $32 |
| Boehringer Ingelheim | 2 | $31 |
| Gilead | 2 | $30 |
| Bayer | 1 | $25 |
| Lundbeck LLC | 1 | $23 |
| Pfizer | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Alkermes, Inc. | 1 | $16 |
| AstraZeneca | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
How this compares
$1,303 in reported general payments places this provider in the 70th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 155 | $215,483 |
| MounjaroTirzepatide | 116 | $126,691 |
| OzempicSemaglutide | 99 | $119,753 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $57,467 |
| FarxigaDapagliflozin Propanediol | 60 | $50,728 |
| EliquisApixaban | 46 | $40,711 |
| LinzessLinaclotide | 55 | $35,761 |
| XareltoRivaroxaban | 45 | $30,976 |
| JardianceEmpagliflozin | 37 | $30,796 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $22,280 |
| BrilintaTicagrelor | 37 | $21,719 |
| EntrestoSacubitril/Valsartan | 21 | $17,884 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 23 | $16,283 |
| JanuviaSitagliptin Phosphate | 22 | $14,299 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $13,643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess | $325 | $251,244210 claims |
| Lilly USA, LLCMounjaro | $75 | $126,691116 claims |
| Novo NordiskOzempic | $63 | $119,75399 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere, Symbicort, Bevespi Aerosphere | $14 | $104,905181 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Spiriva Respimat, Trijardy Xr | $31 | $73,492110 claims |
| GSKTrelegy Ellipta | $84 | $57,46790 claims |
| PfizerEliquis, Lyrica | $22 | $46,93457 claims |
| MerckJanuvia | $48 | $14,29922 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $18 | $8,77013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,706 family providers in Tennessee.
Other family in Bean Station
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.